Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies

Head and Neck

Volumn 35, Issue 8, 2013, Pages 1171-1177

  Barnea, Itay ^a   Ben Yosef, Rahamim ^a   Karaush, Victoria ^a   Benhar, Itai ^b   Vexler, Akiva ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

cetuximab; EGFR; head and neck cancer; prostate cancer; Pseudomonas exotoxin A

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; ZZ PE38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG SAFETY; DRUG TARGETING; FIBROBLAST; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

CETUXIMAB; EGFR; HEAD AND NECK CANCER; PROSTATE CANCER; PSEUDOMONAS EXOTOXIN A;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; EXOTOXINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84880699883     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23093     Document Type: Article

References (29)

1. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
2. de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E, Hernandez Agudo E, Feliu Batlle J, Gonzalez BM,. EGFR and colon cancer: a clinical view. Clin Transl Oncol 2008; 10: 6-13.
3. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
4. Ben-Yosef R, Sarid D, Barnea I, et al. ErbB1-ErbB4 over-expression, ethnicity and predicted outcome in prostate cancer. Targeted Oncol 2008; 3: 13-17.
5. Piyathilake CJ, Frost AR, Manne U, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002; 8: 734-744.
6. Lin H, Jiang J, Liang X, Zhou X, Huang R,. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70: 57-62.
7. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
9. Venook AP, Blanke CD, Niedzwiecki D, et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005; 5: 292-294.
10. Wu AM, Senter PD,. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-1146.
11. Ricart AD, Tolcher AW,. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007; 4: 245-255.
12. Sharkey RM, Goldenberg DM,. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226-243.
13. Schaedel O, Reiter Y,. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 2006; 12: 363-378.
14. Cheson BD,. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol 2009; 16: 299-305.
15. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496.
16. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
17. Mazor Y, Noy R, Wels WS, Benhar I,. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett 2007; 257: 124-135.
18. Bachran D, Schneider S, Bachran C, et al. Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int J Cancer 2010; 127: 1453-1561.
19. Michaelis M, Bliss J, Arnold SC, et al. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res 2008; 14: 6531-6537.
20. Yip WL, Weyergang A, Berg K, Tonnesen HH, Selbo PK,. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007; 4: 241-251.
21. Theuer CP, Kreitman RJ, FitzGerald DJ, Pastan I,. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res 1993; 53: 340-347.
22. Yates SP, Merrill AR,. Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A. Biochem J 2004; 379: 563-572.
23. Ben-Yosef R, Starr A, Karaush V, et al. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 2007; 67: 871-880.
24. Rana S, Sen R, Kalra R, Arora B, Sharma P, Gahlawat S,. Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma. Indian J Pathol Microbiol 2006; 49: 495-499.
25. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4909-4919.
26. Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 0000; 16: 1894-1903.
27. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27: 2983-2990.
28. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719-6729.
29. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13: 5144-5149.